

Edgar Filing: ATHEROGENICS INC - Form 8-K

ATHEROGENICS INC
Form 8-K
August 19, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 19, 2003

ATHEROGENICS, INC.
(Exact Name of Registrant as Specified in its Charter)

Georgia	0-31261	58-2108232
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

8995 Westside Parkway
Alpharetta, GA 30004
(Address of principal executive offices)

Registrant's telephone number, including area code (678) 336-2500

Item 5. Other Events

On August 19, 2003, AtheroGenics, Inc. issued a press release to report that the company completed the sale of \$100 million of its 4.5% Convertible Notes due 2008, which includes the exercise by the initial purchasers of their entire \$20 million over-allotment option. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

Item 7. Exhibits

The following exhibit is filed with this current report on Form 8-K.

Exhibit No.	Description
99.1	- Press Release dated August 19, 2003

Edgar Filing: ATHEROGENICS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ATHEROGENICS, INC.

Date: August 19, 2003

/s/ RUSSELL M. MEDFORD

Russell M. Medford
President and Chief Executive
Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	- Press Release dated August 19, 2003